New Israeli app uses AI technology to empowers cancer patients worldwide

The Israeli company Belong.Life, which specializes in artificial intelligence solutions for the healthcare sector, has launched an innovative app designed to empower cancer patients by offering them advanced support in managing their illness

The BelongAI Dave app uses cutting-edge AI technology and is considered the most advanced AI tool of its kind, providing services via a 24/7 proactive mentor.

Belong.Life co-founder and CEO Eliran Malki said the cutting-edge app combines accessibility with affordability.

“Proximity to hospital or bank account size should not determine priority in answering patients' questions and needs. The BelongAI Dave - Cancer Mentor app will allow us to make personalized cancer support accessible and affordable for everyone,” Malki explained.

The company’s other co-founder, Irad Deutsch, believes the BelongAI Dave will revolutionize proactive support for cancer patients.

The app is connected to an enormous repository of more than two million data points. The vast data includes peer-to-peer exchanges and patient-doctor interactions within the BelongLife community. Access to such a large amount of data allows for highly accurate and patient-specific medical support. AI technology enables constant improvements by the accumulation of previous data.

Cancer has become a serious medical challenge, especially in many Western nations with aging populations. In 2020, The World Cancer Research Fund International estimated that there were around 18 million known cancer cases globally. While cancer affects both genders, statistics show it is slightly more common among men than women.

Known for its advanced medical facilities and know-how, the Jewish state has contributed significantly to medical research and the healthcare sector, including cancer treatments.

In March 2023, Israeli researchers discovered a treatment for pancreatic cancer, one of the world’s most lethal forms of cancer. Hebrew University Faculty of Medicine Prof. Rotem Karni who led the research, explained the importance of the study.

In June 2023, Israeli researchers from Sheba Medical Center and Tel Aviv University announced a breakthrough in fighting lethal skin cancer. The Israel Cancer Research Fund supported the groundbreaking study. Prof. Shoshana Greenberger from the Sheba Medical Center outside Tel Aviv explained that the study focused on the connection between melanoma and the formation of lymph vessels.

“Our main research question was how melanoma impacts the formation of lymph vessels, through which it then metastasizes,” Greenberger said.

Sheba Hospital was recently ranked as the world’s 9th best medical facility, according to Newsweek Magazine. Known for its highly competent staff and use of cutting-edge technologies, the Sheba Hospital was ranked as the best in the Middle East and last September, Newsweek ranked Sheba among the world's top 20 leading "smart hospitals."